tirzepatide vs semaglutide efficacy weight loss diabetes Tirzepatide: Which GLP-1 Wins for Loss? Subcutaneously administered tirzepatide vs semaglutide
Description
Notable Articles of 2024: FLOW trial In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significantly reduced risks of major kidney events, cardiovascular events, and death from any cause while slowing loss of kidney function.
Pre-treatment with a GLP1 receptor-blocking antibody neutralised the CNO-dependent improvement in glucose tolerance but did not affect the reduction in food intake, and an independent group of animals pair-fed to the CNO-treatment group demonstrated attenuated weight loss
Using the correct semaglutide injection sites is not just about comfort
Individual components of metabolic syndrome were also reduced to a greater extent with tirzepatide vs comparators
For people with obstructive sleep apnea, Zepbound may actually improve sleep over time
Our GLP-1 Edge box is a 4-day supply of breakfast, lunch, dinner and snacks to give you an edge reaching your best self
